HK Stocks Movement | CRO Sector Rebounds as Industry Performance Expected to Recover in H2; Morgan Stanley Sees Attractive Valuations in WuXi Group

Stock News11-24

CRO concept stocks collectively rebounded. As of press time, Tigermed (03347) rose 9.19% to HK$39.92; WuXi AppTec (02359) gained 4.43% to HK$106; Pharmaron (03759) climbed 4.15% to HK$21.58; WuXi Biologics (02269) increased 3.27% to HK$31.56.

CMB International believes that the recovery in capital market financing activities, expansion of overseas innovative drug transactions, rebounding domestic R&D demand, and the U.S. interest rate cut cycle could drive a performance recovery for CXO companies in the second half of the year. The firm expects clinical developments of licensed innovative drug pipelines overseas to become a key catalyst for the sector.

Morgan Stanley noted in a report that healthcare stocks have faced sustained selling since mid-September as investors lock in profits and await signals for next year's performance. The bank highlighted that WuXi group stocks, backed by solid fundamentals, now offer more attractive valuations. Morgan Stanley is most bullish on WuXi AppTec, citing its raised earnings guidance, large-scale capacity expansion, and strong involvement in next-generation GLP-1 therapies.

Overall, WuXi AppTec, WuXi Biologics, and WuXi XDC are projected to achieve 2024-27 earnings CAGRs of 24%, 23%, and 37%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment